Everest Medicines (SEHK:1952) Stock Can Revenue Scale Turn Near Profit Durable

Everest Medicines came into this print under pressure, with the stock down about 16% over the past week and roughly 25% over three months. Yet the headline from H1 2026 is not about collapse. It is about a commercial stage biotech that generated CNY 1.15b in revenue while keeping the reported net loss to just CNY 5.94m.

For a company still widely viewed as an early stage drug developer, that gap between modest share price and emerging profit profile is what matters. Investors now have to decide whether the market is properly pricing that shift.

Is Everest Medicines a rare bargain or just cheap for a reason at this share price and loss profile? Compare its current P/S and DCF gap against peers on our valuation analysis for Everest Medicines

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025) CNY 1,147.84m vs. CNY 446.12m (very large increase; revenue is more than 2.5x the prior period)
• Net Income or Loss (H1 2026 vs. H1 2025) Loss of CNY 5.94m vs. loss of CNY 249.79m (loss narrowed meaningfully)
• Basic EPS (H1 2026 vs. H1 2025) Loss of CNY 0.02 per share vs. loss of CNY 0.77 per share (per share loss narrowed)
• Gross Margin ex intangible amortization (H1 2026) Approximately 73.7% (no directly comparable prior period margin disclosed)

Prefer clear visuals instead of scrolling through dense earnings tables and raw figures on Everest Medicines? Get a full picture of its business performance with an at a glance view of revenue trends, margins and profitability in our company report for Everest Medicines.

Everest Medicines Starts To Back Its Growth Story

The bullish story around Everest Medicines is that NEFECON and VELSIPITY can rapidly scale and pull the group toward sustainable profitability. H1 2026 goes a fair way toward proving that. NEFECON has driven most of the CNY 1.15b in revenue and roughly CNY 900m annualised run rate, which lines up with the idea of strong uptake after hospital formulary and NRDL access in China. VELSIPITY only launched in early 2026, and management is already pushing for NRDL inclusion and broader use in mild to moderate ulcerative colitis, which is an early but important marker for the blockbuster argument.

The profitability milestone that bulls wanted is partly visible. Adjusted profit of CNY 97.2m and operating profit of CNY 48.1m, alongside a 73.7% gross margin, indicate that volume from the lead drugs is now supporting a more self funding model.

Compare that shift from near break even to positive adjusted profit and high gross margin with how the street is framing Everest Medicines today. See the consensus price target analysis for Everest Medicines to gauge whether analysts think this earnings profile supports the current HK$23.8 share price or points elsewhere.

Everest Medicines Bears Still Watching Key Pressure Points

The core bearish worry around Everest Medicines is that heavy reliance on licensed assets in China, where price pressure is intense, will leave thin and fragile profitability that depends on constant external deals. H1 shows a reported net loss that is almost flat and an adjusted profit of CNY 97.2m. That suggests operating leverage, but not yet a clear, recurring earnings base once out licensing and non cash items are stripped back.

Bears also flag persistent cash burn and dilution risk. Everest closed June with CNY 1.836b in cash and then received a CNY 770m upfront from the EVER001 out license. That reduces near term funding strain but supports the view that balance sheet comfort is still tied to deal making rather than internally generated cash. Pricing and reimbursement pressure in China remains a live issue, with NRDL negotiations for VELSIPITY and XERAVA still representing unfinished milestones.

With Everest Medicines still loss making on a trailing basis, reliant on deal driven cash and facing pricing pressure in China, you may want to verify the real cash runway and balance sheet strength. Analyze the financial health analysis of Everest Medicines stock.

Stay Ahead Of Your Next Move

If Everest Medicines looks interesting after this earnings profile and shifting loss picture, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a better entry point. Once you own it or any other stock, use the Portfolio Command Center to cut through noise and keep on top of the key fundamental and valuation changes that matter. For a longer term edge, tap into crowd views through the Community and see how other investors are reacting to new data. That way you can review potential catalysts or warning signs early and stay a step ahead of the wider market.

Seeking Alternatives Beyond Everest Medicines?

Fresh stock ideas can move from quiet accumulation to full breakout before most investors react. Screen for under the radar opportunities while the data still matters and get in early.

• Spot potential breakouts before momentum is obvious by scanning a curated pool of resilient companies in the 288 resilient stocks with low risk scores.
• Ride sectors already gathering quiet momentum by filtering for companies with strong cash generation using the 261 high quality undervalued stocks.
• Track where critical infrastructure spending could be heading next by reviewing the hand picked 39 power grid technology and infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com